Product image of Letybo (Botulinum Toxin Type A) supplied by GNH India

Letybo

Active Ingredient:
Botulinum Toxin Type A
Origin:
EU

Letybo (Botulinum Toxin Type A)

Botulinum toxin type A, the active ingredient in Letybo, is a Botulinum toxin presented as a sterile injectable for intramuscular use. It reduces excessive muscle contraction and is employed in adult patients with conditions such as cervical dystonia, spasticity, and chronic migraine.
GNH India supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Croma Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letybo, a botulinum toxin type A product, acts on the neuromuscular junction to alleviate muscle overactivity in several clinical settings.

  • Cervical dystonia: reduces abnormal neck muscle contractions and associated pain.
  • Upper‑limb spasticity: improves range of motion and functional ability.
  • Chronic migraine: decreases frequency of migraine days.
  • Blepharospasm: lessens involuntary eyelid closure.
  • Hyperhidrosis: diminishes excessive sweating in targeted areas.

How It Works

  • Botulinum toxin type A binds to presynaptic nerve terminals at the neuromuscular junction and cleaves SNAP‑25, a protein essential for acetylcholine vesicle fusion. This inhibition prevents acetylcholine release, resulting in temporary paralysis of the targeted skeletal muscle fibers and reduced muscle contraction for several months.

Side Effects

Adverse reactions are generally related to the injection site and the pharmacologic action of the toxin.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Bruising: localized discoloration due to minor bleeding.
  • Headache: transient headache following treatment.
  • Flu‑like symptoms: mild fever or malaise.
  • Localized muscle weakness: temporary reduction in strength near the injection area.

Serious or Rare Side Effects

  • Dysphagia: difficulty swallowing when neck muscles are affected.
  • Respiratory compromise: rare spread of toxin causing breathing difficulties.
  • Allergic reaction: rash, itching, or anaphylaxis.
  • Vision changes: blurred vision or double vision.
  • Systemic toxin spread: generalized muscle weakness beyond the injection site.

Precautions & Warnings

Prior to administration, clinicians should evaluate patient history and specific risk factors.

  • Infection at injection site: avoid injecting into infected or inflamed tissue.
  • Known hypersensitivity: do not use in patients with documented allergy to botulinum toxin or its excipients.
  • Neuromuscular disorders: caution in patients with myasthenia gravis, Lambert‑Eaton syndrome, or ALS.
  • Pregnancy: safety not established; avoid unless clearly needed.
  • Breastfeeding: insufficient data; weigh potential risks and benefits.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Botulinum toxin type A may interact with other agents that affect neuromuscular transmission.

Major Interactions (Avoid)

  • Aminoglycoside antibiotics: may potentiate neuromuscular blockade.
  • Other neuromuscular blocking agents: increased risk of profound muscle weakness.
  • Cholinesterase inhibitors: can reduce the clinical effect of the toxin.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: may increase bruising at injection sites.
  • Antiplatelet agents: similar risk of bleeding.
  • Concurrent botulinum toxin products: cumulative effect may lead to systemic spread.

Frequently Asked Questions

Letybo contains botulinum toxin type A and is used to manage conditions characterized by excessive muscle activity, such as cervical dystonia, upper‑limb spasticity, chronic migraine, blepharospasm, and focal hyperhidrosis. The toxin temporarily weakens the targeted muscles, providing symptom relief and functional improvement.

Botulinum toxin type A blocks the release of acetylcholine at the neuromuscular junction by cleaving the SNAP‑25 protein. This prevents nerve signals from triggering muscle contraction, leading to a localized and reversible reduction in muscle activity that can last several months.

The dose of Letybo is individualized by the prescribing clinician based on the specific indication, muscle groups treated, and patient characteristics. Healthcare providers determine the appropriate units and injection sites to achieve the desired therapeutic effect.

Safety of Letybo in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Letybo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Letybo contains the same active molecule—botulinum toxin type A—as other branded products like Botox® or Dysport®. Differences may lie in formulation, unit potency, approved indications, and regulatory status. Clinicians select a product based on clinical experience, labeling, and specific patient needs.

Letybo should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Proper cold‑chain storage maintains product stability and potency.

Letybo is administered by a trained healthcare professional via intramuscular injection. The clinician selects appropriate injection sites, prepares the sterile solution according to the product label, and injects the calculated dose directly into the targeted muscle or gland.

Serious risks include dysphagia, respiratory compromise, systemic spread of toxin leading to generalized muscle weakness, and severe allergic reactions such as anaphylaxis. Patients should be monitored for these events, especially when treating muscles involved in swallowing or breathing.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A or any excipients, and it should be avoided in patients with active infection at the planned injection site, certain neuromuscular disorders (e.g., myasthenia gravis), or those who are pregnant or breastfeeding unless clearly indicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Botulinum Toxin Type A

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT